Risky decision-making key to entrepreneurs: University of Cambridge researchers

Whether someone will become the next Richard Branson, Steve Jobs or Henry Ford may be down to whether they make risky decisions, scientists at the University of Cambridge have concluded.

In an article, published in the journal Nature, they assert that entrepreneurs are riskier decision-makers than their managerial counterparts. Additionally, the type of decision-making essential to the entrepreneurial process may be possible to teach or enhanced in the future by pharmaceuticals.

Psychological and biomedical research has traditionally considered risk-taking as an abnormal expression of behaviour, as exemplified by its association with substance abuse and bipolar disorder.

However, the Cambridge research, funded by the Wellcome Trust and the Medical Research Council, found entrepreneurs represent an example of highly adaptive risk-taking behaviour which can result in positive outcomes during stressful economic circumstances. This 'functional impulsivity', the ability to make quick decisions under stress, may have evolutionary value as a means of seizing opportunities in a rapidly-changing environment.

Entrepreneurs choose to start their own business ventures rather than working within an existing company. Whilst there is a potential for considerable profit in making the decision to 'go out on their own', these individuals accept the accompanying risks (to finances, reputation, family stability and even self-esteem) as many new ventures fail. The researchers propose that it is these types of decisions which differentiate entrepreneurs from others.

To test their hypothesis, they had 16 entrepreneurs from 'Silicon Fen' (the cluster of high-tech companies in and around Cambridge) and 17 managers complete a computerised neurocognitive assessment measuring various aspects of their decision-making abilities.

On a decision-making task that required 'cold' processes, entrepreneurs and managers performed similarly. ('Cold' processes govern real-life decisions such as when planning the opening of a consulting company or hiring staff.)

The researchers then had the entrepreneurs and managers make 'hot' or risky decisions which involved evaluating rewarding versus punishing outcomes. (For example, the decision between financing one of several potentially excellent but risky business opportunities is a hot decision - it is too difficult for emotions not to play a role.) On this test, although entrepreneurs and managers both made good quality decisions, entrepreneurs were significantly riskier. Entrepreneurs also showed superior cognitive flexibility and higher ratings on questionnaires which measure impulsivity. These cognitive processes are intimately linked to brain neurochemistry, particularly to the neurotransmitter dopamine.

Professor Barbara Sahakian, lead author of the study, said: "This study has shown that not all risk-taking is disadvantageous, particularly when combined with enhanced flexible problem solving. In fact, risky or 'hot' decision-making is an essential part of the entrepreneurial process and may be possible to teach, particularly in young adults where higher risk taking is likely and age-appropriate.

"Additionally, from previous studies we know that drugs can be used to manipulate dopamine levels, leading to changes in risky decision-making. Therefore, our findings also raise the question of whether one could enhance entrepreneurship pharmacologically."

 



Previous articles
Screen Technology reassures stock market and reverses share price fall
Cambridge Uni applies its tech savvy to Formula One racing with Penske
Autonomy to float off consumer division blinkx after record Q1 earnings
Autonomy’s 1H pre-tax profits leap 89%; sees further strong growth through 2008
Silicon Fens shorts: Cox Comms signs up with Autonomy; Cambridge Consultants see Europe as first beneficiary of new consumer diagnostics
Silicon Fen shorts: New CEO for EEDA; Meldex 'in play'?
Keronite to start mass production in China of light alloy coatings with local partner
Briefs: Intercytex part of group to develop US military’s Regenerative Medicine Institute
Celsis 1H07 revenues, profits grow; sees new business from cross-selling
Commercial rents no deterrent as St John's Innovation Centre runs at 90% occupancy
Subscribe

 

Corporate profiles

 • AdventIQ


Mr Peter Wharton
CEO


AdventIQ Limited is a new venture whose mission is to explore the fusion of hardware and software for remote access solutions. Sending keyboard, video and mouse (KVM) signals via IP networks is widely viewed as the future of the KVM industry as it transitions from analogue switching techniques. But

[AdventIQ's profile]


Top20 Index




Currently: 79.47